Azacitidine Injection Shortage: Supply Updates and Manufacturer Availability

What’s in Shortage

Azacitidine Injection (Brand name: AZACITIDINE) is currently listed in the FDA database as being in shortage. This medication is used in oncology and is supplied as an injection. The shortage specifically affects the 100 mg dosage forms. This shortage was initially posted on December 18, 2020, and was most recently updated on February 10, 2026.

Which Manufacturers Are Affected

Supply levels vary significantly across the five manufacturers currently listed:

• Accord Healthcare Inc.: Available. (100 mg, NDC 16729-306-10). Contact: 866-941-7875, option 2.
• Dr. Reddy’s Laboratories, Inc.: Available, but limited to existing customers. (100 mg, NDC 43598-305-62). Contact: 866-732-3952.
• Fresenius Kabi USA, LLC: Available; providers are encouraged to check wholesaler inventory. (100 mg/30 mL, NDC 63323-771-39). Contact: 1-888-386-1300.
• Eugia US LLC: Currently unavailable and on backorder. Recovery date is to be determined (TBD). (100 mg/4 mL, NDC 55150-393-01). Contact: 888-238-7880.
• Teva Pharmaceuticals USA, Inc.: Currently unavailable. Estimated availability is to be determined (TBD). (100 mg, NDC 68001-313-56). Contact: 800-545-8800.

Why There’s a Shortage

The FDA source data does not provide a specific reason for the current supply limitations of Azacitidine Injection.

What Patients Should Do

Patients who rely on this medication should take the following practical steps:

• Consult Your Healthcare Provider: Discuss your treatment schedule with your oncologist or doctor to ensure continuity of care.
• Speak with Your Pharmacist: Ask about current inventory levels and if they can secure supply from the manufacturers that currently have the drug available.
• Contact Manufacturers: If necessary, use the contact numbers provided above to inquire about the most recent availability updates for specific product presentations.

Disclaimer: Patients should always consult their healthcare provider regarding medical advice, dosing, and treatment alternatives.

Source

Information sourced from the FDA Drug Shortage Database.